Share this article
Share this article
PUNE, India, March 8, 2021 /PRNewswire/ Digital Therapeutics Market is valued at USD 1.99 Billion in 2017 and Projected to reach USD 14.54 Billion by 2027 with a CAGR of 22% over the forecast period. Technological advancement in medical sector and demand in digital healthcare facilities are key driving factors for the growth of Digital Therapeutics Market.
: Dario Health, Pear Therapeutics, Omada Health, Click Therapeutics, Akili Interactive, Lark Health, Kaia Health, Cognoa
News: Medisafe, digital therapeutics company raises $30M: February 28, 2021; Medisafe, Israel based digital therapeutics company announced the financing round completion worth $30M led by Alive Israel HealthTech and Sanofi fund, with Menorah Mivtachim, Leumi Partners and Consensus Business Group. The previous investors include 7wireVentures, Merck Ventures, Iool Ventures, Pitango HealthTech, Octopus Ventures, Triventures, Qualcomm Ventures and OurCrowd. The company has
Digital Therapeutic (DTx) Market Worth $6 9 billion by 2025
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
Form D Friday: Boston companies raising funds March 2021 - Boston Business Journal
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Company adds a leading national Integrated Delivery Network (IDN) as a strategic investor.
The financing supports Pear’s continued efforts to expand patient access for its portfolio of Prescription Digital Therapeutics (PDTs), including reSET®, reSET-O® and Somryst® treating addiction and insomnia conditions, respectively.
BOSTON & SAN FRANCISCO–(BUSINESS WIRE)–Pear Therapeutics, Inc., (“Pear” or the “Company”) today announced the second closing of its Series D financing. The second closing included a leading national Integrated Delivery Network (IDN) as a new strategic investor. The national IDN is investing $20 million, bringing the total Series D investment to $100 million.
“Pear is pleased to add one of America’s leading health care providers and health plans to our distinguished list of investors as we continue to expand patient access to our FDA-authorized digital therapeutics,” said Corey McCann, M.D., Ph.D., President and CEO of Pear Therapeutics. �
Pear Therapeutics tags another $20M to December s Series D round
mobihealthnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mobihealthnews.com Daily Mail and Mail on Sunday newspapers.